Kyle Doherty

Dostarlimab-gxly achieved a 100% cCR rate in a phase 2 study for locally advanced dMMR/MSI-H rectal cancer, with a median follow-up of 17.9 months.

Lasofoxifene, a selective ER modulator, is being tested in combination with abemaciclib for ER-positive/HER2-negative metastatic breast cancer with ESR1 mutations.

Enhertu maintained HRQOL and neurological function in HER2-positive metastatic breast cancer patients, regardless of brain metastases status.

Grinch made a special visit to the pupils of Ardnashee School and College

R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.

STRIDE regimen, combining tremelimumab and durvalumab, shows superior overall survival in unresectable HCC compared to sorafenib, with significant long-term benefits.

Daiichi Sankyo and AstraZeneca withdrew their EU application for Dato-DXd in advanced nonsquamous NSCLC due to lack of significant overall survival benefit.

Lifileucel received FDA approval for melanoma, showing a 31.5% ORR in heavily pretreated patients, with a median DOR not reached.

The director of the Hematology/Oncology Fellowship Training Program at Fox Chase Cancer Center discusses palliative care training for hematology/oncology fellows and highlights a pilot study aimed at improving this area of training.

Monjuvi, Revlimid, and Rituxan reduced disease progression risk by 57% in relapsed/refractory follicular lymphoma patients compared to placebo plus Revlimid and Rituxan.